●Background:Replication of severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) requires proteolytic processing of the replicase polyprotein by two viral cysteine proteases, a chymotrypsin-like protease (3CLpro) and a papain-like protease (PLpro). These proteases are important targets for development of antiviral drugs that would inhibit viral replication and reduce mortality associated with outbreaks of SARS-CoV.
PLpro is a cysteine protease located within the non-structural protein 3 (NS3) section of the viral polypeptide. PLPro activity is required to process the viral polyprotein into functional, mature subunits; specifically, PLPro cleaves a site at the amino-terminus of the viral replicase region. In addition to its role in viral protein maturation, PLPro possesses a deubiquitinating and deISGylating activity.
In vivo, this protease antagonizes innate immunity by inhibiting IRF3-induced production of type I interferons.
●Protein Construction:Recombinant 2019-nCoV Papain-like Protease is produced by our E.coli expression system and the target gene encoding Glu1564-Lys1878 is expressed.
●Synonym:Papain-like Protease; PLpro; PL-PRO; pp1a; Replicase polyprotein 1a
●Purity:> 90 % as determined by reducing SDS-PAGE.
●Endotoxin:< 1.0 EU per µg as determined by the LAL method. ●Mol Mass:35.8 kDa ●AP Mol Mass:34 kDa ●Formulation:Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 10 mM Mercaptoethanol [BME], 20% Glycerol, pH 7.5.